[go: up one dir, main page]

ES8506091A1 - Un procedimiento para obtener un polidoma - Google Patents

Un procedimiento para obtener un polidoma

Info

Publication number
ES8506091A1
ES8506091A1 ES533931A ES533931A ES8506091A1 ES 8506091 A1 ES8506091 A1 ES 8506091A1 ES 533931 A ES533931 A ES 533931A ES 533931 A ES533931 A ES 533931A ES 8506091 A1 ES8506091 A1 ES 8506091A1
Authority
ES
Spain
Prior art keywords
polydomas
target antigen
hybridoma
specificity
polydoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES533931A
Other languages
English (en)
Other versions
ES533931A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES8506091A1 publication Critical patent/ES8506091A1/es
Publication of ES533931A0 publication Critical patent/ES533931A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN PROCEDIMIENTO PARA OBTENER UN POLIDOMA.COMPRENDE SEPARAR EL NUCLEO DE UNA PRIMERA CELULA DE HIBRIDOMA QUE PRODUCE UN ANTICUERPO MONOCLONAL CONTRA UN PRIMER DETERMINANTE ANTIGENICO E INSERTAR EL NUCLEO EN EL CITOPLASMA DE UN SEGUNDO HIBRIDOMA QUE PRODUCE UN ANTICUERPO MONOCLONAL CONTRA UN SEGUNDO DETERMINANTE ANTIGENICO.
ES533931A 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma Granted ES533931A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES8506091A1 true ES8506091A1 (es) 1985-06-16
ES533931A0 ES533931A0 (es) 1985-06-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES8504461A1 (es)
FI (2) FI900212A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
JP2755395B2 (ja) * 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JP3431140B2 (ja) * 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
JP2001502895A (ja) * 1996-09-20 2001-03-06 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
HUE030786T2 (en) 2004-03-16 2017-06-28 Temple Univ - Of The Commonwealth System Of Higher Education Substituted phenoxy and phenylthio derivatives for the treatment of proliferative disorders
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
ES2477765T3 (es) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Agentes de unión al anti-cd70 humanizado y usos de los mismos
WO2007011968A2 (en) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
TR201911139T4 (tr) 2013-03-15 2019-08-21 Zymeworks Inc Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7156653B2 (ja) 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
MX2021013657A (es) 2019-05-10 2022-02-21 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
ES545247A0 (es) 1986-05-16
FI900212A7 (fi) 1990-01-15
FI834529A7 (fi) 1983-12-09
ES537257A0 (es) 1986-04-01
ES533930A0 (es) 1985-12-01
JPH0753600A (ja) 1995-02-28
AU1555983A (en) 1983-11-04
ES8604424A1 (es) 1986-02-01
AT394577B (de) 1992-05-11
ES521370A0 (es) 1985-04-16
CA1213229A (en) 1986-10-28
ATA901883A (de) 1991-10-15
GB2128631B (en) 1987-02-25
EP0105360A1 (en) 1984-04-18
EP0105360A4 (en) 1986-07-08
ES8603080A1 (es) 1985-12-01
WO1983003679A1 (en) 1983-10-27
GB2128631A (en) 1984-05-02
ES533931A0 (es) 1985-06-16
IT1219778B (it) 1990-05-24
ES538727A0 (es) 1986-02-01
ES8606655A1 (es) 1986-04-01
JP2562002B2 (ja) 1996-12-11
GB2167086A (en) 1986-05-21
ES527963A0 (es) 1985-02-16
GB8530308D0 (en) 1986-01-22
AU550486B2 (en) 1986-03-20
FI834529A0 (fi) 1983-12-09
GB2167086B (en) 1987-03-04
GB8530309D0 (en) 1986-01-22
ES8503441A1 (es) 1985-02-16
GB2169921B (en) 1987-03-04
ES8504461A1 (es) 1985-04-16
IT8320548A0 (it) 1983-04-12
FI900212A0 (fi) 1990-01-15
GB2169921A (en) 1986-07-23
GB2168998B (en) 1987-03-04
ES8607386A1 (es) 1986-05-16
CH672796A5 (es) 1989-12-29
FI834529L (fi) 1983-12-09
JPH0753119B2 (ja) 1995-06-07
GB8332646D0 (en) 1984-01-11
JPS6312276A (ja) 1988-01-19
GB8530310D0 (en) 1986-01-22
GB2168998A (en) 1986-07-02

Similar Documents

Publication Publication Date Title
ES8506091A1 (es) Un procedimiento para obtener un polidoma
DK164510C (da) Humant hybridom, humant monoklonalt antistof opnaaet derfra, anvendelse af et saadant antistof og fremgangsmaade til fremstilling af et saadant antistof
FI864037A0 (fi) Monoklonala antikroppar mot broestkraefta hos maenniska.
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
NO159888C (no) Monoklonalt antistoff.
ES490944A0 (es) Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento
ES489757A0 (es) Un metodo para la preparacion de un anticuerpo monoclonico.
EP0419574A4 (en) Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same
ES539987A0 (es) Un procedimiento para preparar un anticuerpo monoclonal hu- mano
AU545181B2 (en) Hybridoma for producing monoclonal antibodies
EP0352722A3 (en) Adenocarcinoma antigen binding methods and reagents
KR900701318A (ko) 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체
ES2006109A6 (es) Un procedimiento para preparar un conjugado de inmunoglobulina.
KR890008320A (ko) 알파 2→3 결합을 인지하는 단일클론성 항체
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
FI924576A0 (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
SE8200639L (sv) Forfarande for framstellning av anti-t-lymfocytglobulin
DK102589D0 (da) Antigen, der genkendes af mca 16-88
ES546594A0 (es) Un procedimiento para preparar un anticuerpo monocional anti-urocinasa.
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970519